--- title: "STOCKS | Hong Kong Stocks Close Higher with Tech Sector Leading Gains" type: "News" locale: "en" url: "https://longbridge.com/en/news/282807334.md" description: "Hong Kong stocks closed higher on April 15, 2026, with the Hang Seng Index up 0.29% at 25,947.32 points and the Hang Seng Tech Index rising 1.23% to 4,911.79 points. The total market turnover was 245.588 billion Hong Kong dollars. The innovative drug sector saw significant gains, while shale gas and Foxconn stocks declined. Notable gainers included Xuanzhu Biopharmaceuticals-B (+10.5%) and Rongchang Biopharmaceuticals (+9%). Conversely, Zhihu and Xunlei fell by 8.5%." datetime: "2026-04-15T08:18:02.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/282807334.md) - [en](https://longbridge.com/en/news/282807334.md) - [zh-HK](https://longbridge.com/zh-HK/news/282807334.md) --- # STOCKS | Hong Kong Stocks Close Higher with Tech Sector Leading Gains Hong Kong stocks experienced a mixed trading session on April 15, 2026, with the market opening higher but experiencing fluctuations throughout the day. According to Jin10, the Hang Seng Index closed up 0.29% at 25,947.32 points, while the Hang Seng Tech Index rose 1.23% to 4,911.79 points. The total market turnover for the day was 245.588 billion Hong Kong dollars. In terms of sector performance, the innovative drug sector showed strong gains, and the JD.com concept stocks also moved higher. Conversely, the shale gas sector and Foxconn concept stocks declined. Among individual stocks, Xuanzhu Biopharmaceuticals-B (02575.HK) surged 10.5%, Rongchang Biopharmaceuticals (09995.HK) rose over 9%, and 3SBio (01530.HK) increased by more than 8%. Laopu Gold (06181.HK) gained 6.8%, JD.com (09618.HK) climbed 4.6%, while Alibaba (09988.HK), JD Health (06618.HK), Trip.com Group-S (09961.HK), and Baidu (09888.HK) all rose by over 3%. On the downside, Zhihu (02513.HK) and Xunlei (03317.HK) both fell by 8.5%, New Oriental Education & Technology Group (09901.HK) dropped nearly 6%, and Tianqi Lithium (09696.HK) and Ganfeng Lithium (01772.HK) both declined by 5%. Li Ning (02331.HK) decreased by 4.6%. ### Related Stocks - [02575.HK](https://longbridge.com/en/quote/02575.HK.md) - [09995.HK](https://longbridge.com/en/quote/09995.HK.md) - [159992.CN](https://longbridge.com/en/quote/159992.CN.md) - [159102.CN](https://longbridge.com/en/quote/159102.CN.md) - [588130.CN](https://longbridge.com/en/quote/588130.CN.md) - [159859.CN](https://longbridge.com/en/quote/159859.CN.md) - [516820.CN](https://longbridge.com/en/quote/516820.CN.md) - [512010.CN](https://longbridge.com/en/quote/512010.CN.md) - [588860.CN](https://longbridge.com/en/quote/588860.CN.md) - [520690.CN](https://longbridge.com/en/quote/520690.CN.md) - [560600.CN](https://longbridge.com/en/quote/560600.CN.md) - [588250.CN](https://longbridge.com/en/quote/588250.CN.md) - [159892.CN](https://longbridge.com/en/quote/159892.CN.md) - [00HSI.HK](https://longbridge.com/en/quote/00HSI.HK.md) - [STECH.HK](https://longbridge.com/en/quote/STECH.HK.md) - [01530.HK](https://longbridge.com/en/quote/01530.HK.md) - [06181.HK](https://longbridge.com/en/quote/06181.HK.md) - [09618.HK](https://longbridge.com/en/quote/09618.HK.md) - [JD.US](https://longbridge.com/en/quote/JD.US.md) - [09988.HK](https://longbridge.com/en/quote/09988.HK.md) - [BABA.US](https://longbridge.com/en/quote/BABA.US.md) - [06618.HK](https://longbridge.com/en/quote/06618.HK.md) - [09961.HK](https://longbridge.com/en/quote/09961.HK.md) - [09888.HK](https://longbridge.com/en/quote/09888.HK.md) - [BIDU.US](https://longbridge.com/en/quote/BIDU.US.md) - [ZH.US](https://longbridge.com/en/quote/ZH.US.md) - [XNET.US](https://longbridge.com/en/quote/XNET.US.md) - [09901.HK](https://longbridge.com/en/quote/09901.HK.md) - [EDU.US](https://longbridge.com/en/quote/EDU.US.md) - [09696.HK](https://longbridge.com/en/quote/09696.HK.md) - [002466.CN](https://longbridge.com/en/quote/002466.CN.md) - [01772.HK](https://longbridge.com/en/quote/01772.HK.md) - [002460.CN](https://longbridge.com/en/quote/002460.CN.md) - [02331.HK](https://longbridge.com/en/quote/02331.HK.md) - [688331.CN](https://longbridge.com/en/quote/688331.CN.md) - [688336.CN](https://longbridge.com/en/quote/688336.CN.md) - [HLPD.SG](https://longbridge.com/en/quote/HLPD.SG.md) - [89618.HK](https://longbridge.com/en/quote/89618.HK.md) - [89988.HK](https://longbridge.com/en/quote/89988.HK.md) - [HBBD.SG](https://longbridge.com/en/quote/HBBD.SG.md) - [86618.HK](https://longbridge.com/en/quote/86618.HK.md) - [HTGD.SG](https://longbridge.com/en/quote/HTGD.SG.md) - [TCOM.US](https://longbridge.com/en/quote/TCOM.US.md) - [89888.HK](https://longbridge.com/en/quote/89888.HK.md) - [02390.HK](https://longbridge.com/en/quote/02390.HK.md) - [82331.HK](https://longbridge.com/en/quote/82331.HK.md) ## Related News & Research - [Xuanzhu Biopharmaceutical Wins CSRC Nod for H Share Full Circulation Plan](https://longbridge.com/en/news/282442087.md) - [Xuanzhu Biopharm Wins Green Light for Phase III Anaprazole Trial in H. pylori](https://longbridge.com/en/news/282752451.md) - [RemeGen Wins Fifth China Approval for Flagship ADC in Urothelial Cancer](https://longbridge.com/en/news/282374325.md) - [AbbVie bets on Chinese biopharma’s pain pipeline in $745m bid](https://longbridge.com/en/news/282533515.md) - [China to Let Firms Set New Drug Prices Based on Clinical Value, R&D Costs and Risks](https://longbridge.com/en/news/282939130.md)